Execution

Executing contractual documents

Lawyers work on a huge variety of transactions, but all of them will in some way involve written agreements that will need to be executed by the parties. For this reason, it is very important that lawyers know when a deed is required and fully understand the differences in how deeds and simple contracts are executed.

This subtopic summarises the law, guidance and practice relating to simple contracts and deeds, including in particular:

  1. the key elements that must be present to create a contract

  2. what simple contracts are and how they are executed

  3. what a deed is and the particular transactions for which a deed (rather than a simple contract) is required

  4. the formalities for creating valid deeds

  5. guidance on executing deeds and simple contracts in counterpart

  6. how to circulate pre-signed counterpart signature pages and virtual closings

This subtopic contains execution content based on the law of England and Wales. For execution content for Scottish practitioners, see: Execution—Scotland—overview.

The Practice Note: Executing documents—deeds and simple contracts summarises the law and practice relating to simple contracts and deeds, as

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest Life Sciences News

EFPIA publishes report on economic impact of clinical trials and benefits of increasing EU activity

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published a report assessing the economic and societal contribution of industry-sponsored clinical trials in Europe, estimating that 35,000 additional Europeans could gain access to clinical trials if new EU targets aimed at attracting research are met. According to the report, achieving the 11% increase in trial activity target set by the European Commission, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) would generate an additional €4bn annually for EU healthcare systems and the wider economy, create 18,000 jobs and prevent three million sick days each year, equating to around 500 additional multinational trials over five years and increasing annual trial numbers from 900 to 1,000. The report estimates that industry-sponsored clinical trials currently generate €35.7bn per year across the European Economic Area (EEA), comprising €21.7bn from clinical trial activity, €3.6bn in research and development spillovers and €10.4bn in productivity gains linked to the prevention of 26.9 million sick days annually. The analysis also examines two more ambitious scenarios, finding that a 25% increase in trial activity would deliver an additional €8.9bn in gross value added (GVA) and 79,000 more trial places, while a 50% increase would unlock up to €17.9bn in additional GVA and 158,000 additional places. The report notes that Europe’s share of global industry-sponsored clinical trials declined from 22% in 2013 to 12% in 2023, despite an overall rise in global trial numbers during the same period. The Association of the British Pharmaceutical Industry (ABPI) states that the findings align with its previous UK analysis, which found that industry clinical trials contributed £7.4bn to the UK economy in 2022, including £1.2bn in revenue for the NHS and that restoring activity to 2017 levels would generate an additional £3bn and support 26,000 jobs.

View Life Sciences by content type :

Popular documents